检索结果-南通市图书馆

Major complications after radiofrequency ablation for liver tumors:Analysis of 255 patients

World Journal of Gastroenterology 2009年第21期15卷 2651-2656页

作者： wen-tao kong wei-wei zhang yu-dong qiu tie zhou jun-lan qiu wei zhang yi-tao ding Department of Hepatobiliary Surgery Drum Tower Hospital Medical College of Nanjing University Nanjing 210008 Jiangsu Province China

AIM:To investigate the major complications after radiofrequency ablation(RFA) for the treatment of liver tumors and analyze possible risk factors that precipitate these ***:From March 2001 to April 2008,255 patients with liver tumors(205 male,50 female;age range,18-89 years;mean age,56.0 years) who received RFA were enrolled in this *** these patients,212 had hepatocellular carcinoma,39 had metastatic liver tumors and four had cholangiocellular *** hundred and forty eight patients had a single tumor,and 107 had multiple *** diameter of the tumors ranged 1.3-20 cm(mean,5.1 cm).All patients were treated with a cooled-tip perfusion electrode attached to a radiofrequency generator(Radionics,Burlington,MA,USA).RFA was performed via the percutaneous approach(n = 257),laparoscopy(n = 7),or open surgical treatment(n = 86).The major complications related to RFA were *** resultant data were analyzed to determine risk factors associated these ***:Among the 255 patients,425 liver tumors were treated and 350 RFA sessions were ***-seven(10%) major complications were observed which included 13 cases of liver failure,10 cases of hydrothorax requiring drainage,three casesof tumor seeding,one case of upper gastrointestinal bleeding,one case ofintrahepatic abscess,one case of bile duct injury,one case of cardiac arrest,and five cases of *** patients had more than two *** failure was the most severe complication and was associated with the highest *** patients died due to worsening liver ***-Pugh classification(P = 0.001) and choice of approach(P = 0.045) were related to post-treatment liver failure,whereas patient age,tumor size and number were not significant factors precipitating this ***:RFA can be accepted as a relatively safe procedure for the treatment of liver ***,attention should be paid to possible com

关键词： Complication Hepatocellular carcinoma Metastatic liver tumor Radiofrequency ablation Liverfailure

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

One-year status of hepatic venous pressure gradient measurement from 85 hospitals in China

引用

Portal Hypertension & Cirrhosis 2024年第2期3卷 116-123页

作者： Jitao Wang Ting Cui Linpeng zhang Zhiping Yan Lei Li Jinjun Chen junhui Sun Hua Xiang He Zhu Hao Wu Jiancuo Gengzang Feng zhang wei Wu Guohong Cao Wuhua Guo Haibin Shi Hui Xue Guangjun Huang Qiang yu Meng Niu Huiling Xiang Derun kong wei Gou Xuefeng Luo Fuliang He Min yuan wei Liu Yong Wang Hongjie Hu Xiaoli Zhu tao yu Qinxue Sun wei Qu Ting Lu Deqiang Ma Li zhang jun Ma jun Yang Ketao Mu Xiaoliang Zhu Kai Xiong Huiguo ding Shengjuan Yao Mingsheng Huang Fang Wang Zexin Wang Yong Huang Jianan Li Hongfeng yi Birun Huang Zhongwei Zhao Duiping Feng Yanming Lei Changlong Hou wenbo Guo Shirong Liu Gaojun Teng Kangshun Zhu Fan Wu Xiaogang Hu wenfeng zhang Shaoqi Yang zhouchao Hu Pengfei Pang Shaowu Zhuang weidong Wang Qingliang Zhu Kunpeng zhang Chengyu Liu dongliang Li Chao Ma Hong Jiang Xingong Zhao weixin Ren Zhiwei Wang Lei yu Fuhuang Lin Chaoguang Yan Feng Wang Lei yu Hui Huan wenyong Shen Shaofei He Chengda zhang Jinlun Bao Jiangtao Liu jun Wu Jianbo Zhao Jian zhang Xiaolong Qi Hebei Provincial Key Laboratory of Cirrhosis&Portal Hypertension Xingtai People's HospitalXingtaiHebeiChina Center of Portal Hypertension Department of RadiologyZhongda HospitalSchool of MedicineSoutheast UniversityNanjingJiangsuChina Department of Interventional Therapy Beijing Shijitan Hospital Affiliated to Capital Medical UniversityBeijingChina Department of Intervention Taiyuan Third People's HospitalTaiyuanShanxiChina Department of Intervention Zhongshan Hospital Affiliated to Fudan UniversityShanghaiChina Department of Interventional Medicine The First Hospital of Lanzhou UniversityLanzhouGansuChina Department of Infectious Diseases Nanfang Hospital of Southern Medical UniversityGuangzhouGuangdongChina Hepatobiliary and Pancreatic Intervention Center The First Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiangChina Interventional Vascular Surgery Hunan Provincial People's HospitalChangshaHunanChina Department of Intervention Sixth People's Hospital of ShenyangShenyangLiaoningChina Department of Gastroenterology West China Hospital of Sichuan UniversityChengduSichuanChina Department of Intervention The Fourth People's Hospital of Qinghai ProvinceXiningQinghaiChina Department of Gastroenterology Nanjing Drum Tower HospitalNanjingJiangsuChina Department of Gastroenterology The First Affiliated Hospital of Wenzhou Medical UniversityWenzhouZhejiangChina Department of Radiology Shulan(Hangzhou)HospitalHangzhouZhejiangChina Department of Intervention Mengchao Hepatobiliary Hospital of Fujian Medical UniversityFuzhouFujianChina Department of Interventional Radiology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsuChina Department of Gastroenterology The First Affiliated Hospital of Xi'an Jiaotong UniversityXi'anShaanxiChina Department of Gastroenterology Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityJinanShandongChina Department of Interventional Radiology Fifth Medical Center

Aims:Surveys and research on the applications of the hepatic venous pressure gradient(HVPG)are important for understanding the current status and future development of this technology in *** article aimed to investigate the status of hepatic venous pressure gradient measurement in China in ***:We investigated the overall status of HVPG technology in China-including hospital distribution,hospital level,annual number of cases,catheters used,average cost,indications,and current challenges by using online *** counting the number and percentages of cases of these results,we hope to clarify the current status of HVPG measurements in ***:According to the survey,85 hospitals in China used HVPG technology in 2022 distributed across 29 provinces.A total of 4989 HVPG measurements were performed in all of the surveyed hospitals in 2022,of which 2813 cases(56.4%)were measured *** average cost of HVPG measurement was 5646.8±2327.9 *** the clinical teams who performed the measurements(sometimes multiple per hospital),94.3%(82/87)used the balloon method,and the majority of the teams(72.4%,63/87)used embolectomy ***:This survey clarified the clinical application status of HVPG in China and confirmed that some medical institutions in China have established a foundation for this *** is still necessary to continue promoting and popularizing this technology in the future.

关键词： application status hepatic vein pressure gradient questionnaire survey

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Coevolutionary insights between promoters and transcription factors in the plant and animal kingdoms

引用

Zoological Research 2022年第5期43卷 805-812页

作者： Jing-Song zhang Hai-Quan Wang Jie Xia Kun Sha Shu-tao He Hao Dai Xiao-Hu Hao yi-wei zhou qiu Wang Ke-Ke ding zhang-Lei Ju wen Wang Luo-Nan Chen Key Laboratory of Systems Biology Shanghai Institute of Biochemistry and Cell BiologyCenter for Excellence in Molecular Cell ScienceChinese Academy of SciencesShanghai 200031China Department of General Surgery Shanghai General Hospital of Shanghai Jiao Tong University School of MedicineShanghai 200080China College of Information Engineering Zhejiang University of TechnologyHangzhouZhejiang 310023China Naval Healthcare Information Center Faculty of Military Health ServicesNaval Medical UniversityShanghai 200433China Bioinformatics Core of Excellence Department GenScript Biotech CorporationNanjingJiangsu 211110China Waigaoqiao Free Trade Zone Wuxi BiologicsShanghai 200131China Department of Cardiology Tongji HospitalTongji University School of MedicineShanghai 200065China School of Ecology and Environment Northwestern Polytechnical UniversityXi’anShaanxi 710072China State Key Laboratory of Genetic Resources and Evolution Kunming Institute of ZoologyChinese Academy of SciencesKunmingYunnan 650223China Key Laboratory of Systems Health Science of Zhejiang Province School of Life ScienceHangzhou Institute for Advanced StudyUniversity of Chinese Academy of SciencesChinese Academy of SciencesHangzhouZhejiang 310024China Guangdong Institute of Intelligence Science and Technology ZhuhaiGuangdong 519031China

The divergence and continuous evolution of plants and animals contribute to ecological *** and transcription factors(TFs) are key determinants of gene regulation and transcription ***,theevolutionary trajectories and relationships of promoters and TFs are still poorly understood. Here, we conducted extensive analysis of large-scale multi-omics sequences in 420 animal species and 223 plant species spanning nearly a billion years of evolutionary history. Results showed that promoter GC-contentandTFisoelectricpoints,as features/signatures that accompany long biological evolution, exhibited increasing growth in animal cells but a decreasing trend in plant cells. Furthermore, the evolutionary trajectories of promoter and TF signatures in the animal kingdom provided further evidence that Mammalia as well as Aves evolved directly from the ancestor Reptilia. The strong correlation between promoter and TF signatures indicates that promoters and TFs formed antagonistic coevolution in the animal kingdom, but mutualistic coevolution in the plant kingdom. The distinct coevolutionary patterns potentially drive the plant-animal divergence, divergent evolution and ecological diversity.

关键词： Molecularevolution Coevolution Promoter Transcription factor Plant-animal divergence

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

CEPC Technical Design Report

引用

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves weiming An Rui An Daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-jun Bi yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai wenyong Cai Wujun Cai yijian Cai yizhou Cai yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi junsong Cang Guofu Cao Jianshe Cao Antoine Chance Xuejun Chang yue Chang Zhe Chang Xinyuan Chang wei Chao Auttakit Chatrabhuti yimin Che yuzhi Che Bin Chen Danping Chen Fuqing Chen Fusan Chen Gang Chen Guoming Chen Hua-Xing Chen Huirun Chen Jinhui Chen Ji-yuan Chen Kai Chen Mali Chen Mingjun Chen Mingshui Chen Ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen ying Chen yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng yunlong Chi Pietro Chimenti wen Han Chiu Guk Cho Ming-Chung Chu Xiaotong Chu Ziliang Chu Guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi Ling-yun Dai Xinchen Dai Xuwen Dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran ding Siqin dingl Yadong ding Haiyi dong Jianin AGH University of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui University HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu University Institute of ScienceVaranasi Bandirma Onyedi Eylul University Bandirma Beihang University Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal University Beijing Brown University ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad University Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo University Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central China Normal University WuhanHubei Central South University ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan China academy of engineering physics MianyangSichuan China building materials academy Beijing China Center of Advanced Science and Technology Beijing China Institute of Atomic Energy Beijing China Jiliang University HangzhouZhejiang China Nuclear Instrument CO. LTDBeijing China University of Geosciences Beijing China University of Geosciences WuhanHubei China University of Mining and Technology XuzhouJiangsu China West Normal University NanchongSichuan Chongqing University Department of PhysicsChongqing Chulalongkorn University Bangkok City University of Hong kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell University IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille Dalian Minzu University DalianLiaoning Dalian University of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP JINR) Dubna East China University Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by China,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV Linac,a 1.1 GeV Damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The Linac and Damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial

引用

Signal Transduction and Targeted Therapy 2021年第6期6卷 1845-1855页

作者： Huijie Bian Zhao-Hui Zheng ding wei Aidong wen Zheng zhang Jian-Qi Lian wen-Zhen Kang Chun-qiu Hao Jing Wang Rong-Hua Xie Ke dong Jie-Lai Xia Jin-Lin Miao wen Kang Guoquan Li Di zhang Mingru zhang Xiu-Xuan Sun Likun ding Kui zhang junfeng Jia Jin ding Zhiqin Li Yanyan Jia Lin-Na Liu Zhe zhang Zhao-wei Gao Hong Du Na Yao Qing Wang Ke Wang Jie-Jie Geng Bin Wang Ting Guo Ruo Chen yu-Meng Zhu Li-Juan Wang Qian He Rui-Rui Yao ying Shi Xiang-Min Yang Jian-Sheng zhou yi-Nan Ma Ya-tao Wang Xue Liang Fei Huo Zhe Wang Yang zhang Xu Yang Ye zhang Lu-Hua Gao Ling Wang Xiao-Chun Chen Hao Tang Shuang-Shuang Liu Qing-yi Wang Zhi-Nan Chen Ping Zhu National Translational Science Center for Molecular Medicine and Department of Cell Biology Fourth Military Medical UniversityXi'anChina Department of Clinical Immunology Xijing HospitalFourth Military Medical UniversityXi'anChina Department of Pharmacy Xijing HospitalFourth Military Medical UniversityXi'anChina Center for Infectious Diseases Tangdu HospitalFourth Military Medical UniversityXi'anChina Department of Nuclear Medicine Xijing HospitalFourth Military Medical UniversityXi'anChina department of Clinical Diagnosis Tangdu HospitalFourth Military Medical UniversityXKanChina College of Military Preventive Medicine Fourth Military Medical UniversityXi'anChina Department of Pharmaceutics Tangdu HospitalFourth Military Medical UniversityXi'anChina Department of Pathology Fourth Military Medical UniversityXi'anChina Jiangsu Pacific Meinuoke Biopharmaceutical Co.Ltd ChangzhouChina Department of Foreign languages Fourth Military Medical UniversityXi'anChina

Recent evidence suggests that CD147 serves as a novel receptor for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)*** CD147 via anti-CD147 antibody could suppress the in vitro SARS-CoV-2 *** is a humanized anti-CD147 IgG_(2) monoclonal antibody,which may effectively prevent SARS-CoV-2 infection in coronavirus disease 2019(COVID-19)***,we conducted a randomized,double-blinded,placebo-controlled phase 1 trial to evaluate the safety,tolerability,and pharmacokinetics of meplazumab in healthy subjects,and an open-labeled,concurrent controlled add-on exploratory phase 2 study to determine the efficacy in COVID-19 *** phase 1 study,59 subjects were enrolled and assigned to eight cohorts,and no serious treatment-emergent adverse event(TEAE)or TEAE grade≥3 was *** serum and peripheral blood Cmax and area under the curve showed non-linear pharmacokinetic *** obvious relation between the incidence or titer of positive anti-drug antibody and dosage was observed in each *** biodistribution study indicated that meplazumab reached lung tissue and maintained>14 days stable with the lung tissue/cardiac blood-pool ratio ranging from 0.41 to *** the exploratory phase 2 study,17 COVID-19 patients were enrolled,and 11 hospitalized patients were involved as concurrent *** meplazumab treatment significantly improved the discharged(P=0.005)and case severity(P=0.021),and reduced the time to virus negative(P=0.045)in comparison to the control *** results show a sound safety and tolerance of meplazumab in healthy volunteers and suggest that meplazumab could accelerate the recovery of patients from COVID-19 pneumonia with a favorable safety profile.

关键词： patients dosage phase

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

引用

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-yi Su Sun-Bin Ling Qiao-Nan Shan Xu-Yong wei Rui Wang Chang-Ku Jia Li Zhuang Tian Shen Li-Min ding Zhi-Dan Xu Lai-Bang Luo Li-Bo Sun Guang-Ming Li Tai-Shi Fang Nan Jiang Kun zhang Zhao-Jie Su Zhi-Hai Peng Ren lang tao Jiang Qiang He Lin-Sen Ye Yang Yang yu-Ting He wen-Zhi Guo Liu-Gen lan Xu-Yong Sun dong Chen Zhi-Shui Chen Da-wei zhou Shao-jun Ye Qi-Fa Ye Min Tian Jian-Hua Shi Bo Wang Jiang Liu Qian Lu wei Rao Jin-Zhen Cai tao Lv Jia-yin Yang Pu-Sen Wang Lin Zhong Jing-Sheng Ma Qi-Gen Li Sheng-dong Wu Chang-Jiang Lu Cai-De Lu dong-Hua zhang Xuan Wang Zi-Qiang Li Mu-Jian Teng jun-Jie Li wen-tao Jiang Jian-Hua Li Quan-Bao zhang Ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-Hua Song Zhi-Ren Fu wei qiu Guo-yue Lv Rui-Peng Song Ji-zhou Wang Zheng Wang Jian zhou Gang Chen ying-Peng Zhao Li Li Ze-Min Hu Qi-Jie Luo Zhong-zhou Si Bin Xie Xiao-Shun He Zhi-Yong Guo Shu-Sen Zheng Xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China Liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and Liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma Liver transplantation Conversion

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

射频技术在肝细胞癌临床应用中的选择、疗效与思考

引用

中华肝胆外科杂志 2011年第7期17卷 531-533页

作者：张炜炜孔文韬丁义涛周铁南京大学医学院附属鼓楼医院肝胆外科 210008

射频消融为治疗肝细胞癌的重要方法，具有微创性，可重复性，疗效确切等优点。对于不适宜手术及肝移植的早期肝细胞癌患者，许多中心已将其作为一种有效的手段。笔者回顾了射频治疗肝细胞癌的适应证、技术及疗效。我们体会，对于射频治... 详细信息

射频消融为治疗肝细胞癌的重要方法，具有微创性，可重复性，疗效确切等优点。对于不适宜手术及肝移植的早期肝细胞癌患者，许多中心已将其作为一种有效的手段。笔者回顾了射频治疗肝细胞癌的适应证、技术及疗效。我们体会，对于射频治疗，合理选择患者、优化治疗方案、完全灭活肿瘤与术后密切随访非常重要。新技术的应用，如人工胸水与腹水辅助穿刺、实时超声造影术中引导，腹腔镜与开腹射频，更有助于拓展射频治疗的适应证，减少术后并发症。

关键词：射频肝细胞癌疗效

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

The first data release(DR1) of the LAMOST regular survey

引用

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-Li Luo Yong-Heng Zhao Gang Zhao Li-Cai Deng Xiao-wei Liu yi-Peng Jing Gang Wang Hao-Tong zhang Jian-Rong Shi Xiang-Qun Cui Yao-Quan Chu Guo-Ping Li Zhong-Rui Bai yue Wu Yan Cai Shu-yun Cao Zi-Huang Cao Jeffrey L.Carlin Hai-yuan Chen Jian-jun Chen Kun-Xin Chen Li Chen Xue-Lei Chen Xiao-Yan Chen ying Chen Norbert Christlieb Jia-Ru Chu Chen-zhou Cui yi-Qiao dong Bing Du dong-wei Fan Lei Feng Jian-Ning Fu Peng Gao Xue-Fei Gong Bo-Zhong Gu Yan-Xin Guo Zhan-wen Han Bo-Liang He Jin-Liang Hou Yong-Hui Hou wen Hou Hong-Zhuan Hu Ning-Sheng Hu Zhong-wen Hu Zhi-ying Huo Lei Jia Fang-Hua Jiang Xiang Jiang Zhi-Bo Jiang Ge Jin Xiao kong Xu kong Ya-Juan Lei Ai-Hua Li Chang-Hua Li Guang-wei Li Hai-Ning Li Jian Li Qi Li Shuang Li Sha-Sha Li Xin-Nan Li Yan Li yin-Bi Li Ye-Ping Li yuan Liang Chien-Cheng Lin Chao Liu Gen-Rong Liu Guan-Qun Liu Zhi-Gang Liu wen-Zhi Lu yu Luo yin-Dun Mao Heidi Newberg Ji-jun Ni Zhao-Xiang Qi Yong-jun Qi Shi-yin Shen Huo-Ming Shi Jing Song yi-Han Song ding-Qiang Su Hong-jun Su Zheng-Hong Tang Qing-Sheng tao yuan Tian Dan Wang Da-Qi Wang Feng-Fei Wang Guo-Min Wang Hai Wang Hong-Chi Wang Jian Wang Jia-Ning Wang Jian-Ling Wang Jian-Ping Wang jun-Xian Wang Lei Wang Meng-Xin Wang Shou-Guan Wang Shu-Qing Wang Xia Wang Ya-Nan Wang You Wang yue-Fei Wang You-Fen Wang Peng wei Ming-Zhi wei Hong Wu Ke-Fei Wu Xue-Bing Wu yu-Zhong Wu Xiao-Zheng Xing Ling-Zhe Xu Xin-Qi Xu Yan Xu Tai-Sheng Yan De-Hua Yang Hai-Feng Yang Hui-Qin Yang Ming Yang Zheng-qiu Yao Yong yu Hui yuan Hai-Bo yuan Hai-Long yuan wei-Min yuan Chao Zhai En-Peng zhang Hua-wei zhang Jian-Nan zhang Li-Pin zhang wei zhang Yong zhang Yan-Xia zhang Zheng-Chao zhang Ming Zhao Fang zhou Xu zhou Jie Zhu Yong-Tian Zhu Si-Cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in june 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in june 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

人工胸腔积液超声引导经皮射频消融治疗膈顶部肝癌

引用

临床肿瘤学杂志 2007年第3期12卷 188-190页

作者：周铁仇毓东张炜炜周建新孔文韬丁义涛南京大学医学院附属鼓楼医院肝胆外科

目的：经皮超声引导射频消融是治疗肝脏肿瘤的一种有效的微创方法。但当肿瘤位于肝膈顶部时，由于肺脏气体的干扰肿瘤难以显示，治疗受到了限制。本文将评估射频结合人工胸腔积液治疗肝膈顶部肿瘤的安全性与可行性，并初步探讨其临床应... 详细信息

目的：经皮超声引导射频消融是治疗肝脏肿瘤的一种有效的微创方法。但当肿瘤位于肝膈顶部时，由于肺脏气体的干扰肿瘤难以显示，治疗受到了限制。本文将评估射频结合人工胸腔积液治疗肝膈顶部肿瘤的安全性与可行性，并初步探讨其临床应用价值。方法：15例原发性肝细胞肝癌患者，男性12例，女性3例，肿瘤均位于肝膈顶部。采用超声引导下冷循环射频结合人工胸腔积液的方法对肿瘤进行治疗。术后1月对所有治疗患者均进行增强CT或磁共振检查。结果：所有病例均安全完成射频治疗，未发生手术相关的并发症。随访时间2-18个月，11例患者存活。结论：人工胸腔积液结合经皮射频消融术可能是治疗肝脏膈顶部肿瘤一种安全可行的方法，值得进一步研究。

关键词：人工胸腔积液射频消融肝细胞性肝癌肝膈顶部

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Data release of the LAMOST pilot survey

引用

Research in Astronomy and Astrophysics 2012年第9期12卷 1243-1246页

作者： A-Li Luo Hao-Tong zhang Yong-Heng Zhao Gang Zhao Xiang-Qun Cui Guo-Ping Li Yao-Quan Chu Jian-Rong Shi Gang Wang Jian-Nan zhang Zhong-Rui Bai Xiao-Yan Chen Feng-Fei Wang Yan-Xin Guo Jian-jun Chen Bing Du Xiao kong Ya-Juan Lei yin-Bi Li yi-Han Song yue Wu Yan-Xia zhang Xin-Lin zhou Fang Zuo Peng Du Lin He wen Hou yi-Qiao dong Jian Li Guang-wei Li Shuang Li Jing Song yuan Tian Meng-Xin Wang Yong-Hui Hou Zhi-ying Huo Hong-Zhuan Hu Ning-Sheng Hu Zhong-wen Hu Lei Jia Fang-Hua Jiang Xiang Jiang Zi-Bo Jiang Ge Jin Ai-Hua Li Qi Li yin-Dun Mao Zheng-Hong Tang Qing-Sheng tao Liang-Ping Tu Da-Qing Wang Dan Wang Jian-Ping Wang Lei Wang Shou-Guan Wang Shu-Qing Wang Ya-Nan Wang You Wang yue-Fei Wang Ming-Zhi wei Xiang-Xiang Xue Xiao-Zheng Xing Ling-Zhe Xu Xin-Qi Xu Yan Xu De-Hua Yang Shi-Hai Yang Zheng-qiu Yao Yong yu Hui yuan Chao Zhai En-Peng zhang Jing zhang Li-Ping zhang weizhang Yong zhang Zhen-Chao zhang Ming Zhao Fang zhou Yong-Tian Zhu Jie Zhu Si-Cheng Zou National Astronomical Observatories Chinese Academy of Sciences Beijing 100012 China lal @ lamost o rg Nanjing Institute of Astronomical Optics and Technology National Astronomical ObservatoriesChinese Academy of Sciences Nanjing 210042 China University of Science and Technologyof China Hefei 230026 China Shanghai Astronomical Observatory Chinese Academy of Sciences Shanghai 200030 China Institute of Architecture Design and Research Chinese Academy of Sciences Beijing 100190China

This paper describes the data release of the LAMOST pilot survey, which includes data reduction, calibration, spectral analysis, data products and data access. The accuracy of the released data and the information about the FITS headers of spectra are also introduced. The released data set includes 319 000 spectra and a catalog of these objects.

关键词： techniques: spectroscopic survey — data reduction — data release

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：